Sotera Health delivered a strong performance in Q3 2025, reporting solid revenue growth across its business segments and expanding profitability. Sterigenics and Nordion achieved double-digit growth, while Nelson Labs improved segment income despite a revenue decline. Adjusted EPS rose significantly year-over-year.

Sotera Health reported Q2 2025 revenue of $294.3 million, up 6.4% year-over-year, with net income of $8.0 million and Adjusted EBITDA rising 9.8% to $150.7 million. The quarter saw strong Sterigenics growth, improved margins, and increased cash holdings.

Sotera Health reported a solid start to 2025 with net revenues increasing 2.6% to $255 million compared to the prior year quarter, driven by growth in the Sterigenics and Nordion segments. The company reported a net loss of $13 million, primarily due to a settlement related to ethylene oxide claims. Adjusted EBITDA saw an 8.8% increase, and Adjusted EPS grew by $0.01 to $0.14. The company reaffirmed its full-year 2025 outlook.

Sotera Health reported a decrease in net revenues for the fourth quarter of 2024, falling by 6.5% to $290 million. Net income also decreased to $12 million, or $0.04 per diluted share, compared to $39 million, or $0.14 per diluted share, in the same quarter of the previous year. Adjusted EBITDA saw a decrease of 8.3% to $153 million, and Adjusted EPS was $0.21, a decrease of $0.02 per diluted share.

Sotera Health reported an 8.5% increase in net revenues, reaching $285 million for Q3 2024, compared to $263 million in Q3 2023. Net income was $17 million, or $0.06 per diluted share, a significant improvement from the net loss of $14 million, or $0.05 per diluted share, in the same quarter last year. The company reaffirmed its 2024 net revenue and Adjusted EBITDA outlook ranges.

Sotera Health reported an 8% increase in net revenues to $277 million for Q2 2024. However, net income decreased to $9 million, or $0.03 per diluted share, primarily due to charges associated with debt refinancing. Adjusted EBITDA increased by 7% to $137 million, while Adjusted EPS declined slightly to $0.19.

Sotera Health reported a solid start to 2024 with a 12.5% increase in net revenues to $248 million and a rise in net income to $6 million, or $0.02 per diluted share. The company reaffirmed its 2024 outlook, focusing on strategic priorities amidst market headwinds.

Sotera Health's Q4 2023 net revenues increased by 23.3% to $310 million compared to the same period last year. Net income was $39 million, a significant improvement from the net loss of $320 million in Q4 2022. Adjusted EBITDA increased by 28.7% to $167 million, and Adjusted EPS was $0.26, up by $0.01 per diluted share.

Sotera Health reported a 6% increase in net revenues to $263 million for Q3 2023, but experienced a net loss of $14 million, or $0.05 per diluted share, due to a $35 million legal settlement and higher interest expenses. Adjusted EBITDA increased by 7% to $134 million, while Adjusted EPS decreased to $0.21. The company reaffirmed its 2023 outlook, anticipating results at the lower end of the previously announced range.

Sotera Health reported a decrease in second-quarter net revenues by 4% to $255 million, primarily due to Nordion Cobalt-60 harvest schedule timing. Net income decreased to $24 million, or $0.08 per diluted share. The company has adjusted its full-year 2023 net revenue outlook to $1.035 billion to $1.055 billion and Adjusted EBITDA to $520 million to $535 million due to continued volume softness.

Sotera Health reported a decrease in first-quarter net revenues by 6.8% to $221 million, primarily driven by the anticipated timing of Nordion Cobalt-60 harvest schedules. Net income decreased to $3 million, or $0.01 per diluted share, compared to $31 million, or $0.11 per diluted share in the first quarter of the previous year. The company reaffirms its 2023 outlook, expecting revenue and adjusted EBITDA growth of 5% to 9%.

Sotera Health reported a 4.3% increase in net revenues to $252 million for Q4 2022 compared to $241 million in Q4 2021. However, the company experienced a net loss of $320 million, or $1.14 per diluted share, due to a $408 million legal reserve. Adjusted EBITDA increased by 4.0% to $130 million, and Adjusted EPS was $0.25, an increase of $0.02 per diluted share.

Sotera Health reported a 10% increase in net revenues to $249 million for Q3 2022, with net income at $25 million, or $0.09 per diluted share. Adjusted EPS improved to $0.23. The company is adjusting its full-year 2022 net revenue growth outlook to 7% - 8% and Adjusted EBITDA growth to 4% - 6%.

Sotera Health's Q2 2022 net revenues increased by 6% to $267 million, and net income was $30 million, or $0.11 per diluted share. Adjusted EBITDA increased by 1% to $136 million, and Adjusted EPS increased to $0.27. The company narrowed its full-year 2022 net revenues outlook to $1.0 to $1.022 billion and Adjusted EBITDA outlook to $515 to $525 million.

Sotera Health reported a 12% increase in net revenues to $237 million for Q1 2022, with net income rising to $31 million, or $0.11 per diluted share. The company reaffirmed its 2022 financial outlook, focusing on execution and capacity building to meet future demand.

Sotera Health reported a 13.1% increase in net revenues to $226 million for the third quarter of 2021, compared to $200 million in the same period last year. Net income attributable to Sotera Health was $27 million, or $0.10 per diluted share, compared to net income of $0.01 million, or $0.00 per diluted share in the third quarter of 2020. Adjusted EBITDA increased by 16.1% to $117 million. The company is narrowing its full-year 2021 revenue growth outlook to 12%-14% and Adjusted EBITDA growth to 13%-14%.

Sotera Health reported a strong start to 2021 with double-digit revenue and Adjusted EBITDA growth. Net revenues for Q1 2021 increased by 13% to $212 million, and net income was $11 million, or $0.04 per diluted share. The company reaffirmed its 2021 outlook.

Sotera Health reported a 12% increase in Q4 2020 net revenues to $217 million compared to Q4 2019. The company's net loss was $44 million, or $0.17 per diluted share, which included a $44 million charge related to debt paydown. Adjusted EBITDA increased by 20% to $113 million, and Adjusted EPS was $0.09, an increase of $0.04 per diluted share.